Insight: Industry Presentations

Web Panel Discussion: Non-Immuno-Oncology and Immuno-Oncology Partnering and Development: What's the Role of Non-IO in an IO World?
January 30, 2017 | Jeffrey M. Bockman, PhD, SVP, Oncology Practice Head, Defined Health
Immuno-Oncology Partnering: Tipping Point or Tip of the Iceberg?
December 15, 2016 | Jeffrey M. Bockman, PhD, SVP, Oncology Practice Head, Defined Health
Web Panel Discussion: What's Hot & What's Not in Immuno-Oncology Licensing Part 2
December 10, 2016 | Jeffrey M. Bockman, PhD, SVP, Oncology Practice Head, Defined Health
Antibiotics – The Next Big Thing, Again?
November 29, 2016 | Danielle Marra, MS, MBA, Associate Principal, Defined Health
With Dov. A. Goldstein, MD, MBA, Managing Partner, Aisling Capital LLC, Dennis J. Purcell, Founder and Senior Advisor, Aisling Capital LLC and Daniel S. Shapiro, MD, Professor of Internal Medicine, University of Nevada School of Medicine, Department of Internal Medicine
Pricing and Paying for Progress: Disrupting the BioPharma Business Model
November 18, 2016 | Ed Saltzman, Executive Chairman, Defined Health
Pricing and Paying for Progress: Disrupting the BioPharma Business Model, LES Annual Meeting, October 25, 2016, Vancouver
October 25, 2016 | Ed Saltzman, Executive Chairman, Defined Health
LES (USA and Canada) Names Ed Saltzman 2016 Recipient of the LES Frank Barnes Mentor Award
October 3, 2016 | Defined Health
The Future is Now: Dealing in a Transformed Healthcare Environment
September 13, 2016 | Ed Saltzman, Executive Chairman, Defined Health
27th Annual Cancer Progress Key Conclusions & Recommendations Whitepaper
August 18, 2016 | Defined Health
Supportive Neurology: Valuing Increased Function and Improved QoL in Treatment of Non-Core Symptoms of Neurological Disease
August 4, 2016 | Ginger S. Johnson, PhD, Chief Executive Officer, Defined Health
With Todd Sherer, PhD, Chief Executive Officer, The Michael J. Fox Foundation for Parkinson's Research
New Biological Therapies for Asthma: Do the Benefits Justify the Cost?
May 17, 2016 | Aruni S. Arachchige Don, Senior Consultant, Defined Health
With John Oppenheimer, FACAAI, MD, Director of Clinical Research, Pulmonary and Allergy Associates and Clinical Professor of Medicine, Rutgers University and Ed Saltzman, President, Defined Health
Connecting drug pricing to value: The industry's greatest challenge
April 5, 2016 | Ed Saltzman, Executive Chairman, Defined Health
With Joseph Damond – Senior VP, International Affairs, Biotechnology Innovation Organization (BIO) and Paul K. Gallagher – President, Compass Strategic Consulting, Inc.
After inflammation, fibrosis: Will biopharma follow nature's lead?
April 4, 2016 | David J. Lomb, PhD, Associate Principal, Defined Health
With Matthias Corbascio – VP, Inflammation, IsletOne Therapeutics, Donnie McGrath – VP, Search and Evaluation, Business Development, Bristol-Myers Squibb, Elias Papatheodorou – CEO, Genkyotex S.A and Hans T. Schambye – CEO, Galecto Biotech AB
Neurodegenerative disorders: Are we finally scaling the wall?
April 4, 2016 | Ginger S. Johnson, PhD, Chief Executive Officer, Defined Health
Management of Diabetes: Beyond the Insulin and Incretin Pathways
April 4, 2016 | Michael C. Rice, MS, MBA, Principal, Defined Health
Reconsidering Relevance in Oncology: Is the Market Immune to Your Non-IO Assets?
February 18, 2016 | Joel S. Sandler, PhD, Associate Principal, Defined Health
With Jeffrey M. Bockman, PhD, Vice President, Defined Health and Michael C. Rice, MS, MBA, Senior Consultant, Defined Health
The Future is Now: Dealing in a Transformed Healthcare Environment
November 10, 2015 | Ed Saltzman, Executive Chairman, Defined Health
Web Panel Discussion: What's Hot & What's Not in Immuno-Oncology Licensing Part 1
October 20, 2015 | Jeffrey M. Bockman, PhD, SVP, Oncology Practice Head, Defined Health
Boosting Immuno-Oncology Therapies to the Next Level: New Combinations & Approaches
July 23, 2015 | Jeffrey M. Bockman, PhD, SVP, Oncology Practice Head, Defined Health
Web Panel Discussion: What's Hot & What's Not in Gene Therapies for Rare Disorders
May 6, 2015 | Michael C. Rice, MS, MBA, Principal, Defined Health
Changes to Biopharma's External Ecosystem That Will Bring Permanent Changes to the Biopharmaceutical Industry
April 30, 2015 | Ed Saltzman, Executive Chairman, Defined Health
Aducanumab: Hype, or Headway for the Alzheimer’s Amyloid Hypothesis?
April 13, 2015 | Ginger S. Johnson, PhD, Chief Executive Officer, Defined Health
The Dash to Treat NASH, The Next Big Global Epidemic
March 9, 2015 | David J. Lomb, PhD, Associate Principal, Defined Health
2014 Cardiometabolic Projects To Watch
November 21, 2014 | Defined Health
Foundational Changes in the Biopharmaceutical and Healthcare Macro Environments . . . and the Impacts on Licensing & Business Development
October 7, 2014 | Ed Saltzman, Executive Chairman, Defined Health
The Future of Immuno-Oncology: Perspectives from Academia and Industry
September 19, 2014 | Jeffrey M. Bockman, PhD, SVP, Oncology Practice Head, Defined Health
What’s Hot & What’s Not in Oncology Licensing
September 18, 2014 | Jeffrey M. Bockman, PhD, SVP, Oncology Practice Head, Defined Health
Migraine Prophylaxis: The Race is On
June 13, 2014 | Ginger S. Johnson, PhD, Chief Executive Officer, Defined Health
Establishing Proof of Relevance for Early Stage Deal Making
April 22, 2014 | Ed Saltzman, Executive Chairman, Defined Health
Pharma Steps Up Early on Relevance Data
April 8, 2014 | Ed Saltzman, Executive Chairman, Defined Health
Addressing Cognitive Deficits Across CNS Disorders: Potential to Improve Overall Outcomes and QoL
February 20, 2014 | Ginger S. Johnson, PhD, Chief Executive Officer, Defined Health
A Pre-Cancer Progress 2014 High Level Snapshot of Challenges & Opportunities in the Oncology Market
January 30, 2014 | Jeffrey M. Bockman, PhD, SVP, Oncology Practice Head, Defined Health
Heaven Can Wait: Progress Against Progression in CKD
December 11, 2013 | Defined Health
From Pariah to Darling: Biopharma Finally Courts Immunotherapies
December 5, 2013 | Jeffrey M. Bockman, PhD, SVP, Oncology Practice Head, Defined Health
Connecting Proof of Relevance to Proven Value for Pharma
September 25, 2013 | Ed Saltzman, Executive Chairman, Defined Health
CNS Orphans and Disease Subsegments: The Road Less Traveled
June 12, 2013 | Ginger S. Johnson, PhD, Chief Executive Officer, Defined Health
A High Level Snapshot of Challenges & Opportunities in the Oncology Market
May 15, 2013 | Jeffrey M. Bockman, PhD, SVP, Oncology Practice Head, Defined Health
Changing AML Outcomes via Personalized Medicine: Transforming Cancer Management with Genetic Insight
February 28, 2013 | Michael C. Rice, MS, MBA, Principal, Defined Health
Antibiotics 2013: Who Stands to GAIN?
February 20, 2013 | Defined Health
Novel Therapeutics for Fibrotic Disease: Has Their Time Finally Arrived?
May 24, 2012 | David J. Lomb, PhD, Associate Principal, Defined Health